BOPA Guidance on use of H2 antagonists for hypersensitivity
In response to the nationwide shortage of ranitidine and other H2 antagonists, BOPA have produced a guideline on the use of H2 antagonists for the prevention and management of hypersensitivity to assist with clinical decision making.
Click here to view the guideline.
We are also planning a national service evaluation to monitor the impact of the shortage – details to follow soon. Watch this space!